Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)
July 23, 2020 09:50 AM EDTUpdated 12:10 PM
Bioregnum
Pharma
Opinion

The phar­ma world's cham­pi­on patent wall builder is called out for their 'drip-feed' strat­e­gy to safe­guard the next megablock­buster fran­chise

By all ac­counts, Ab­b­Vie holds the ti­tle as a mas­ter builder of patent walls. Its work on Hu­mi­ra has been both leg­endary and ex­tra­or­di­nar­i­ly …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times